Advisory Panel
Coverage of Advisory Panel in the Nexus archive.
- Peptides get their regulatory closeup
An advisory panel to the Food and Drug Administration will meet to recommend whether specialized pharmacies should be permitted to manufacture certain wellness peptides. The discussion centers on regulatory oversight for these products.
- Peptides get their regulatory closeup
An FDA advisory panel will meet to discuss recommendations on allowing specialized pharmacies to produce popular wellness peptides. The meeting aims to determine regulatory guidelines for these peptides.
- PACE Keeps Chechen Dissident on Advisory Panel After LGBTQ+ and ‘Honor Killing’ Comments
The Parliamentary Assembly of the Council of Europe (PACE) retained Ruslan Kutayev on its advisory panel despite his controversial remarks dismissing the plight of women and LGBTQ+ individuals fleeing violence in Chechnya. Kutayev's comments sparked criticism for downplaying the severity of the issue.
- Scientists take centre stage at ‘alternative’ climate talks to phase out fossil fuels
Scientists have launched a new advisory panel to assist countries and released a report with recommendations for transitioning to clean energy, as highlighted in a Nature article published on April 30, 2026. The initiative focuses on phasing out fossil fuels through climate talks.
- FDA to weigh lifting restrictions on some MAHA-favored peptides
The FDA is considering lifting restrictions on certain peptides favored by MAHA, with an advisory panel meeting in July to discuss allowing compounding pharmacies to manufacture these peptides for conditions like ulcerative colitis, wound healing, and obesity. The decision aims to address safety concerns while expanding access to treatments.